Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beam Therapeutics (BEAM) FCF Margin (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed FCF Margin for 7 consecutive years, with 83.35% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 17191.0% to 83.35% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 257.65% through Dec 2025, up 29035.0% year-over-year, with the annual reading at 257.65% for FY2025, 29035.0% up from the prior year.
  • FCF Margin for Q4 2025 was 83.35% at Beam Therapeutics, up from 808.46% in the prior quarter.
  • The five-year high for FCF Margin was 2505.11% in Q1 2022, with the low at 834266.67% in Q1 2021.
  • Average FCF Margin over 5 years is 82644.9%, with a median of 499.96% recorded in 2023.
  • The sharpest move saw FCF Margin crashed -43598333bps in 2021, then soared 83677178bps in 2022.
  • Over 5 years, FCF Margin stood at 22.59% in 2021, then tumbled by -2385bps to 561.38% in 2022, then surged by 106bps to 32.74% in 2023, then plummeted by -880bps to 255.26% in 2024, then surged by 67bps to 83.35% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 83.35%, 808.46%, and 959.08% for Q4 2025, Q3 2025, and Q2 2025 respectively.